Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Estrogen and Cooperation, Competitiveness, and Risk Preferences (FELICIA)

28. oktober 2020 opdateret af: Frederik Graff, RWTH Aachen University

The Effect of Estrogen Levels on Cooperative and Competitive Decision Making and Risk Preferences

This study observes the effects of female cycle hormones on cooperation, competitiveness and risk preferences under experimental conditions. Especially, the causal effect of estradiol is isolated.

Studieoversigt

Status

Ukendt

Detaljeret beskrivelse

Behavioural theories assume that, as a result of natural selection, women undergo a brief, unconscious change in some psychological aspects during ovulation. This short-term change, "ovulatory shift", is assumed to aim to increase the probability of successful reproduction in the decisive days of the female cycle. Amongst others, it is assumed that women behave particularly uncooperatively and particularly competitively towards other women during the fertile days. Though, empirical evidence is ambiguous.

The effect on risk preferences is unclear. Theory generally assumes that female risk aversion increases in the fertile days. However, empirical studies find partly positive and partly negative correlations.

Within the scope of this study, estradiol levels which are collected in the clinical treatment of patients in the Clinic for Gynaecological Endocrinology and Reproductive Medicine are to be linked with the behavioural economic measures of cooperation, competitiveness, and risk preferences, which are collected using questionnaires or a computer-based decision task.

The aim of the research project is to quasi-experimentally isolate the effect of estradiol on competitiveness, cooperation and risk preferences of women.

No study known to us has ever been able to realize a comparable quasi-experimental design which is necessary to isolate the causal effect of estradiol on different behavioural measures.

In the experimental group, a sample of approx. 50 women in fertility treatment (In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI), long Gonadotropin releasing Hormone (GnRH) agonist protocol) is surveyed. This allows us to create a quasi-experimental design in which the estradiol level is exogenously manipulated and regularly measured.

A random sample of 30 male students of Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen University serves as a control group.

We realize a longitudinal section design with measurement repetitions, which allows inter- and intrapersonal comparisons. A three-stage procedure with two measuring points and a preliminary clarification meeting is planned.

The following measuring instruments are used to record competitiveness, cooperation and risk preference: SOEP Risk Attitude, Social Value Orientation German A, The cooperative and competitive Personality Scale German, Risk aversion, Willingness to compete.

Undersøgelsestype

Observationel

Tilmelding (Forventet)

80

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Aachen, Tyskland, 52074
        • Rekruttering
        • RWTH Aachen University Hospital
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Benjamin Rösing

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Women in fertility treatment

Beskrivelse

Inclusion Criteria:

Patients

  1. female
  2. patient in fertility treatment according to Long GnRH Agonist Protocol
  3. 18 years and older
  4. written declaration of consent
  5. persons who are contractually capable and mentally able and willing to follow the instructions of the study staff
  6. understanding of the German language (written and spoken)

Control group

  1. male
  2. 18 Years and older
  3. written declaration of consent
  4. persons who are contractually capable and mentally able and willing to follow the instructions of the study staff
  5. understanding of the German language (written and spoken)

Exclusion Criteria:

Patients

  1. Illiterate
  2. pregnant and breastfeeding women
  3. persons who are accommodated in an institution on official or court order
  4. persons in a dependent or employment relationship with the auditor
  5. simultaneous participation in another clinical trial

Control group

  1. Illiterate
  2. persons who are accommodated in an institution on official or court order
  3. persons in a dependent or employment relationship with the auditor
  4. simultaneous participation in another clinical trial

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: Andet
  • Tidsperspektiver: Fremadrettet

Kohorter og interventioner

Gruppe / kohorte
female patients
women in fertility treatment according to Long GnRH Agonist Protocol
control group
random sample of male students

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change of E2 [mg/l]
Tidsramme: Approx. 10 days after application of GnRH agonist and again approx. 14 days later
Change of blood concentration of estradiol (E2) in mg/l
Approx. 10 days after application of GnRH agonist and again approx. 14 days later
Change of LH [mg/l]
Tidsramme: Approx. 10 days after application of GnRH agonist and again approx. 14 days later
Change of blood concentration of the luteinizing hormone (LH) in mg/l
Approx. 10 days after application of GnRH agonist and again approx. 14 days later
Change of Prog [mg/l]
Tidsramme: Approx. 10 days after application of GnRH agonist and again approx. 14 days later
Change of blood concentration of progesterone (Prog) in mg/l
Approx. 10 days after application of GnRH agonist and again approx. 14 days later
Change of Cooperation 1
Tidsramme: Approx. 10 days after application of GnRH agonist and again approx. 14 days later
Change of willingness to cooperate measured via the Social Value Orientation German A (Murphy et al. 2011)
Approx. 10 days after application of GnRH agonist and again approx. 14 days later
Change of Competitiveness 1
Tidsramme: Approx. 10 days after application of GnRH agonist and again approx. 14 days later
Change of willingness to compete measured via the cooperative and competitive Personality Scale German (Lu et al. 2006)
Approx. 10 days after application of GnRH agonist and again approx. 14 days later
Change of Risk Preference 1
Tidsramme: Approx. 10 days after application of GnRH agonist and again approx. 14 days later
Change of Risk preferences measured via the SOEP Risk Attitude (DIW Berlin)
Approx. 10 days after application of GnRH agonist and again approx. 14 days later
Change of Cooperation 2
Tidsramme: Approx. 10 days after application of GnRH agonist and again approx. 14 days later
Change of willingness to cooperate measured via the cooperative and competitive Personality Scale German (Lu et al. 2006)
Approx. 10 days after application of GnRH agonist and again approx. 14 days later
Change of Competitiveness 2
Tidsramme: Approx. 10 days after application of GnRH agonist and again approx. 14 days later
Change of willingness to compete measured via the Willingness to compete measure based on Niederle & Vesterlund (2007)
Approx. 10 days after application of GnRH agonist and again approx. 14 days later
Change of Risk Preference 2
Tidsramme: Approx. 10 days after application of GnRH agonist and again approx. 14 days later
Change of Risk preferences measured via the Risk aversion measure by Holt & Laury (2002)
Approx. 10 days after application of GnRH agonist and again approx. 14 days later

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Benjamin Rösing, Dr., RWTH Aachen

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

8. oktober 2018

Primær færdiggørelse (Forventet)

30. december 2021

Studieafslutning (Forventet)

30. december 2021

Datoer for studieregistrering

Først indsendt

21. juni 2018

Først indsendt, der opfyldte QC-kriterier

30. juni 2018

Først opslået (Faktiske)

12. juli 2018

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. oktober 2020

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

28. oktober 2020

Sidst verificeret

1. oktober 2020

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 18-053

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

Ingen

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner